Skip to main content

Table 3 Plasma lipid concentrations in the control sample, grouped by LPL genotype.

From: The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion

  

SS (n = 120)

SX + XX (n = 41)

p-value

Age

 

45.4 ± 18.69 (120)

50.8 ± 21.67 (41)

0.131

BMI

 

25.5 ± 4.38 (68)

25.0 ± 3.19 (25)

0.615

TG*

Total

92.1 ± 36.66 (120)

87.9 ± 41.30 (41)

0.544

 

VLDL

47.8 ± 30.01 (98)

47.3 ± 30.70 (35)

0.934

 

LDL

31.0 ± 12.30 (98)

27.0 ± 11.37 (35)

0.099

 

HDL

15.7 ± 4.83 (117)

14.8 ± 5.00 (41)

0.303

C*

Total

184.8 ± 35.19 (120)

181.3 ± 41.01 (41)

0.654

 

VLDL

11.3 ± 8.17 (98)

10.6 ± 6.59 (35)

0.796

 

LDL

123.7 ± 27.00 (98)

117.5 ± 40.53 (35)

0.406

 

HDL

52.6 ± 15.33 (117)

53.9 ± 10.34 (41)

0.553

TG/HDL-C

2.05 ± 1.51 (117)

1.75 ± 1.08 (41)

0.211

  1. *Lipid measurements expressed in mg/dL. Total cholesterol assessed by Wilcoxon two sample test.
  2. TC, total cholesterol; TG, triglyceride; VLDL-C, very low density lipoprotein – cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL, high density lipoprotein; BMI, body mass index; SS, individuals homozygous for the Ser447 allele; SX+XX, individuals that carry either one or two 447X alleles.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X